Get the Stockscreener App
15.64
0.57%
-0.09
After Hours:
15.60
-0.04
-0.26%
Arcutis Biotherapeutics Inc stock is traded at $15.64, with a volume of 3.06M.
It is down -0.57% in the last 24 hours and up +14.24% over the past month.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
See More
Previous Close:
$15.73
Open:
$15.1
24h Volume:
3.06M
Relative Volume:
1.38
Market Cap:
$1.85B
Revenue:
$59.61M
Net Income/Loss:
$-262.14M
P/E Ratio:
-3.9898
EPS:
-3.92
Net Cash Flow:
$-247.49M
1W Performance:
-9.54%
1M Performance:
+14.24%
6M Performance:
+68.17%
1Y Performance:
+57.82%
1-Day Range:
$14.76
$16.11
1-Week Range:
$14.76
$17.75
52-Week Range:
$6.99
$17.75
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
15.64 | 1.85B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Seborrhoeic Dermatitis Market Growth to Accelerate in Forecast - openPR.com
How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85% - MSN
Why IBD 50's Arcutis Is Outplaying The Biotech Tape And Just Reentered Its Buy Zone - MSN
Are Medical Stocks Lagging Cardinal Health (CAH) This Year? - Yahoo Finance
Leading Immuno-Dermatology Player Arcutis Set for Major Investor Presentation at Needham Healthcare - Stock Titan
Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference - TradingView
Arcutis Biotherapeutics CEO sells $64,413 in stock - Investing.com
Arcutis Biotherapeutics CEO sells $64,413 in stock By Investing.com - Investing.com UK
Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
Arcutis throws to Odell Beckham Jr., the latest face of Zoryve foam - Medical Marketing and Media
Arcutis Biotherapeutics shares jump - MSN
Arcutis biotherapeutics CEO Todd Franklin Watanabe sells shares worth $21,137 By Investing.com - Investing.com South Africa
Arcutis biotherapeutics CEO Todd Franklin Watanabe sells shares worth $21,137 - Investing.com India
What's Going On With Arcutis Biotherapeutics Stock Monday? - Benzinga
ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age - Quantisnow
Arcutis Biotherapeutics Unit Gets Health Canada Approval for Atopic Dermatitis Treatment - Marketscreener.com
Arcutis Biotherapeutics: Topical Derm Player Continues To Execute (NASDAQ:ARQT) - Seeking Alpha
Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $19.00 at Jefferies Financial Group - Defense World
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 7.1% Following Analyst Upgrade - Defense World
Jefferies lifts Arcutis stock price target to $19, retains Buy rating - Investing.com Canada
Jefferies lifts Arcutis stock price target to $19, retains Buy rating By Investing.com - Investing.com South Africa
Hand Eczema Clinical and Non-Clinical Studies, Key Companies, - openPR
Brokerages Set Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Target Price at $18.00 - Defense World
Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up - Simply Wall St
Arcutis Biotherapeutics announces new data from two posters at 2025 AAD - TipRanks
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting - The Manila Times
Arcutis Biotherapeutics Inc (ARQT) Unveils Promising Data on ZORYVE® Cream and Foam at AAD 2025 - GuruFocus.com
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic ... - The Bakersfield Californian
Breakthrough Phase 3 Results: New Treatment Shows 97% Success Rate in Major Skin Conditions - StockTitan
Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average - Yahoo Finance
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? - MSN
Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherape - GuruFocus.com
Seborrhoeic Dermatitis Clinical and Non-Clinical Studies, Key - openPR
Arcutis Biotherapeutics CEO Todd Watanabe sells $327,019 in stock - Investing.com India
Arcutis Biotherapeutics (ARQT) – Research Analysts’ Recent Ratings Updates - Defense World
Arcutis Biotherapeutics Inc Stock: Executives Sell Shares Following Strong Results - sharewise
Arcutis Biotherapeutics director sells $130,048 in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics executive sells $49,407 in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics executive sells $49,407 in stock - Investing.com India
Arcutis Biotherapeutics’ general counsel Matsuda sells $42,520 in stock - Investing.com
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):